CELERAMAB Trademark

Trademark Overview


On Thursday, January 15, 2026, a trademark application was filed for CELERAMAB with the United States Patent and Trademark Office. The USPTO has given the CELERAMAB trademark a serial number of 99597248. The federal status of this trademark filing is NEW APPLICATION - ASSIGNED TO EXAMINER as of Wednesday, May 13, 2026. This trademark is owned by CeleramAb Inc. The CELERAMAB trademark is filed in the Chemical Products category with the following description:

Biochemical reagents used for non-medical purposes
celeramab

General Information


Serial Number99597248
Word MarkCELERAMAB
Filing DateThursday, January 15, 2026
Status638 - NEW APPLICATION - ASSIGNED TO EXAMINER
Status DateWednesday, May 13, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesBiochemical reagents used for non-medical purposes

Classification Information


International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status Code6 - Active
Class Status DateThursday, January 15, 2026
Primary Code001
First Use Anywhere DateSaturday, October 12, 2024
First Use In Commerce DateWednesday, February 5, 2025

Trademark Owner History


Party NameCeleramAb Inc
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressMiddleton, WI 53562-5125
US

Trademark Events


Event DateEvent Description
Thursday, January 15, 2026NEW APPLICATION ENTERED
Thursday, January 15, 2026APPLICATION FILING RECEIPT MAILED
Tuesday, May 5, 2026NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, May 13, 2026ASSIGNED TO EXAMINER